Abstract Search

ea0063p838 | Adrenal and Neuroendocrine Tumours 3 | ECE2019

(131) I-MIBG therapy in metastatic paraganglioma and phaeochromocytoma: a 4-year single centre experience

Mazo Estefania Santos , Lanchas Isabel , Begona Miguel , Barrio Javier Pi , Crespo Guillermo , Moreira Manuela , Garcia-Hierro Victor , Manuel Javier Sanchez

Retrospective study of patients with metastatic/progressive pheochromocytoma (PCC) and paraganglioma (PGL) treated with (131) I MIBG in our hospital during 20152018 period.Methods: There are no established criteria for establishing PCC/PGL as malignant apart from de presence of metastases at diagnosis. Radionuclide therapy (131) I-metaiodobenzylguanidine (MIBG) is frequently used in this patients when surgery is not possible. Indication of MIBG tre...

0 shares

ea0037ep678 | Pituitary: basic and neuroendocrinology | ECE2015

Long-term safety, tolerability, and efficacy of extended release somatostatin analogues

Gonzalez Javier , Garcia-Centeno Rogelio , Arnoriaga Maria , Picallo Maria , Ramirez Maria Laura , Andia Victor Manuel , Olmedilla Yoko Lucia , Lopez Aurelio , Monereo Susana

Introduction: The main indications for the somatostatin analogues (SST-A) are acromegalies and/or neuroendocrine tumors. They can increase fecal fats, which could lead to the loss of fat soluble vitamins. There are few published studies showing the effects of the long-term use.Methods: Retrospective study of patients with SST-A indicated from our endocrinology department in the last 10 years. We analysed indications and different epidemiological, clinica...

0 shares

ePoster

Endocrine Abstracts

(131) I-MIBG therapy in metastatic paraganglioma and phaeochromocytoma: a 4-year single centre experience

Long-term safety, tolerability, and efficacy of extended release somatostatin analogues

BiosciAbstracts